Protocol Ledger

NCT06821542 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

Interventional Phase III clinical trial protocol NCT06821542 sponsored by Incyte in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-04 Enrollment: 9 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06821542
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)9 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06821542
Protocol FieldVerified Registry Value
NCT IdentifierNCT06821542
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment9 participants (ACTUAL)
Registered Start Date2025-06-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06821542
Hospital Research SiteLocationSite Profile
Universitair Ziekenhuis LeuvenLeuven, BelgiumOpen Hospital Dossier ->
Fakultni nemocnice Hradec KraloveHradec Králové, CzechiaOpen Hospital Dossier ->
Turku University HospitalTurku, FinlandOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI